Pular para o conteúdo

Semaglutide Lowered Heart Filling Pressures in a Small Obesity-Related Heart Failure Trial, Plus New Tirzepatide MRI Data From SUMMIT

9 de novembro de 2026 · 7 min

Notas do episódio

Two new sets of heart-failure data on GLP-1-based drugs were presented at the American Heart Association's Scientific Sessions 2026 in Chicago on November 8, 2026. In CAMEO-SEMA, a Mayo Clinic-led, double-blind trial published in Nature Medicine, 81 adults with obesity and heart failure with preserved ejection fraction (HFpEF) were randomized to semaglutide 2.4 mg weekly or placebo for 52 weeks. Pressure inside the left side of the heart during low-intensity exercise, measured by catheter, fell by an average of 9.8 mmHg on semaglutide and rose 0.9 mmHg on placebo (a difference of 10.6 mmHg), resting pressure also fell more, and 53.7% of people on semaglutide versus 7.4% on placebo had normal pressures at rest and during exercise at 52 weeks. A 49-person MRI substudy reported improvements in left atrial function and heart filling. We also cover a new three-dimensional MRI analysis from Lilly's tirzepatide SUMMIT trial, which found that left atrial volume and right ventricular mass decreased compared with placebo. These are small studies of pressure and imaging measures, not hospitalizations or deaths, the reports we have do not include side-effect data, and the two drugs were not compared with each other.

Sources

  • Nature Medicine (Nov 8, 2026), Borlaug et al., hemodynamic effects of semaglutide in HFpEF and obesity (CAMEO-SEMA): nature.com
  • Nature Medicine (Nov 8, 2026), Ghanbari et al., CAMEO-SEMA cardiac MRI substudy: nature.com
  • ClinicalTrials.gov, NCT05371496 (CAMEO-SEMA): clinicaltrials.gov
  • Radcliffe Cardiology (Nov 8, 2026), SUMMIT: tirzepatide and cardiac remodelling in HFpEF, interview with Dr. Milton Packer: radcliffeckm.com
  • American College of Cardiology (Nov 16, 2024), original SUMMIT results: acc.org
  • American Heart Association, Scientific Sessions 2026 late-breaking science program: professional.heart.org

Cover: original code-generated illustration (no photo).

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

Todos os episódios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.